Cargando…
Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion
BACKGROUND: Hepatic arterial infusion (HAI) of oxaliplatin, leucovorin, and fluorouracil (FOLFOX) plus sorafenib has a more desirable effect versus sorafenib for hepatocellular carcinoma (HCC) patients with portal vein invasion. However, considering the high cost of hepatic arterial infusion of chem...
Autores principales: | Li, Meiyue, Lin, Shen, Wilson, Leslie, Huang, Pinfang, Wang, Hang, Lai, Shubin, Dong, Liangliang, Xu, Xiongwei, Weng, Xiuhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985441/ https://www.ncbi.nlm.nih.gov/pubmed/33767976 http://dx.doi.org/10.3389/fonc.2021.562135 |
Ejemplares similares
-
Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels
por: Weng, Xiuhua, et al.
Publicado: (2020) -
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
por: Qin, Shukui, et al.
Publicado: (2018) -
Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Ahn, Young Eun, et al.
Publicado: (2021) -
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
por: Kermiche-Rahali, Sabrina, et al.
Publicado: (2013) -
Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Deng, Min, et al.
Publicado: (2023)